CA2368593A1 - Anti-inflammatory therapy for inflammatory mediated infection - Google Patents

Anti-inflammatory therapy for inflammatory mediated infection Download PDF

Info

Publication number: CA2368593A1
Authority: CA; Canada
Prior art keywords: inflammatory; viral; agent; hiv; group
Prior art date: 1999-05-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002368593A

Other languages

English (en)

French (fr)

Inventor

Peter A. Anton

Janis V. Giorgi

Michael A. Poles

Julie E. Elliott

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of California San Diego UCSD

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-14

Filing date

2000-05-12

Publication date

2000-11-23

2000-05-12 Application filed by Individual filed Critical Individual

2000-11-23 Publication of CA2368593A1 publication Critical patent/CA2368593A1/en

Status Abandoned legal-status Critical Current

Links

230000002757 inflammatory effect Effects 0.000 title claims abstract description 64
230000001404 mediated effect Effects 0.000 title claims abstract description 29
208000015181 infectious disease Diseases 0.000 title claims description 84
238000011861 anti-inflammatory therapy Methods 0.000 title description 2
238000000034 method Methods 0.000 claims abstract description 161
239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 93
229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 92
238000004519 manufacturing process Methods 0.000 claims abstract description 48
230000002401 inhibitory effect Effects 0.000 claims abstract description 43
230000004913 activation Effects 0.000 claims abstract description 33
239000000203 mixture Substances 0.000 claims abstract description 20
206010065764 Mucosal infection Diseases 0.000 claims abstract description 18
210000004027 cell Anatomy 0.000 claims description 197
241000725303 Human immunodeficiency virus Species 0.000 claims description 180
241000700605 Viruses Species 0.000 claims description 111
230000003612 virological effect Effects 0.000 claims description 91
210000001519 tissue Anatomy 0.000 claims description 79
102000004127 Cytokines Human genes 0.000 claims description 73
108090000695 Cytokines Proteins 0.000 claims description 73
KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims description 67
230000003110 anti-inflammatory effect Effects 0.000 claims description 62
239000003443 antiviral agent Substances 0.000 claims description 57
229960004963 mesalazine Drugs 0.000 claims description 57
102000019034 Chemokines Human genes 0.000 claims description 53
108010012236 Chemokines Proteins 0.000 claims description 53
102000005962 receptors Human genes 0.000 claims description 51
108020003175 receptors Proteins 0.000 claims description 51
230000010076 replication Effects 0.000 claims description 47
108090000765 processed proteins & peptides Proteins 0.000 claims description 45
150000007523 nucleic acids Chemical class 0.000 claims description 43
102000039446 nucleic acids Human genes 0.000 claims description 41
108020004707 nucleic acids Proteins 0.000 claims description 41
108020004414 DNA Proteins 0.000 claims description 36
208000031886 HIV Infections Diseases 0.000 claims description 36
230000007423 decrease Effects 0.000 claims description 36
230000000770 proinflammatory effect Effects 0.000 claims description 36
206010061598 Immunodeficiency Diseases 0.000 claims description 31
208000029462 Immunodeficiency disease Diseases 0.000 claims description 31
230000007813 immunodeficiency Effects 0.000 claims description 31
241001430294 unidentified retrovirus Species 0.000 claims description 30
230000002496 gastric effect Effects 0.000 claims description 28
210000004400 mucous membrane Anatomy 0.000 claims description 28
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 26
229960003433 thalidomide Drugs 0.000 claims description 26
208000037357 HIV infectious disease Diseases 0.000 claims description 25
230000003247 decreasing effect Effects 0.000 claims description 25
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 25
-1 larnivudine (3TC) Chemical compound 0.000 claims description 24
102000004196 processed proteins & peptides Human genes 0.000 claims description 24
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
102000009410 Chemokine receptor Human genes 0.000 claims description 21
108050000299 Chemokine receptor Proteins 0.000 claims description 21
241000713311 Simian immunodeficiency virus Species 0.000 claims description 21
210000004969 inflammatory cell Anatomy 0.000 claims description 20
238000000338 in vitro Methods 0.000 claims description 19
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 19
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 18
WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 claims description 18
239000003795 chemical substances by application Substances 0.000 claims description 17
241000713666 Lentivirus Species 0.000 claims description 16
239000008194 pharmaceutical composition Substances 0.000 claims description 16
230000007115 recruitment Effects 0.000 claims description 16
229920001184 polypeptide Polymers 0.000 claims description 15
230000002458 infectious effect Effects 0.000 claims description 14
150000003431 steroids Chemical class 0.000 claims description 14
229960002555 zidovudine Drugs 0.000 claims description 14
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 14
102000004190 Enzymes Human genes 0.000 claims description 13
108090000790 Enzymes Proteins 0.000 claims description 13
238000001727 in vivo Methods 0.000 claims description 13
239000003446 ligand Substances 0.000 claims description 13
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 12
230000010354 integration Effects 0.000 claims description 12
238000010839 reverse transcription Methods 0.000 claims description 11
230000009385 viral infection Effects 0.000 claims description 11
102000000844 Cell Surface Receptors Human genes 0.000 claims description 10
108010001857 Cell Surface Receptors Proteins 0.000 claims description 10
230000000692 anti-sense effect Effects 0.000 claims description 10
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims description 10
208000035475 disorder Diseases 0.000 claims description 10
230000004927 fusion Effects 0.000 claims description 10
239000003112 inhibitor Substances 0.000 claims description 10
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 10
229960000616 diflunisal Drugs 0.000 claims description 9
230000003993 interaction Effects 0.000 claims description 9
238000001990 intravenous administration Methods 0.000 claims description 9
229960000953 salsalate Drugs 0.000 claims description 9
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 8
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 8
230000003092 anti-cytokine Effects 0.000 claims description 8
WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims description 8
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 8
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 8
NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical group C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 8
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 8
239000000829 suppository Substances 0.000 claims description 8
102000003675 cytokine receptors Human genes 0.000 claims description 7
108010057085 cytokine receptors Proteins 0.000 claims description 7
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 7
230000017610 release of virus from host Effects 0.000 claims description 7
239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 7
230000007486 viral budding Effects 0.000 claims description 7
108010061833 Integrases Proteins 0.000 claims description 6
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 6
108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 6
108091023040 Transcription factor Proteins 0.000 claims description 6
102000040945 Transcription factor Human genes 0.000 claims description 6
229960001680 ibuprofen Drugs 0.000 claims description 6
239000002850 integrase inhibitor Substances 0.000 claims description 6
229940124524 integrase inhibitor Drugs 0.000 claims description 6
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 6
HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims description 6
229960002009 naproxen Drugs 0.000 claims description 6
238000007911 parenteral administration Methods 0.000 claims description 6
UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims description 6
238000011200 topical administration Methods 0.000 claims description 6
102000053642 Catalytic RNA Human genes 0.000 claims description 5
108090000994 Catalytic RNA Proteins 0.000 claims description 5
241000792859 Enema Species 0.000 claims description 5
239000005557 antagonist Substances 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
239000007920 enema Substances 0.000 claims description 5
229940095399 enema Drugs 0.000 claims description 5
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 5
229960000905 indomethacin Drugs 0.000 claims description 5
229960002702 piroxicam Drugs 0.000 claims description 5
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 5
229960004618 prednisone Drugs 0.000 claims description 5
108091092562 ribozyme Proteins 0.000 claims description 5
239000011734 sodium Substances 0.000 claims description 5
229910052708 sodium Inorganic materials 0.000 claims description 5
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 5
229960000894 sulindac Drugs 0.000 claims description 5
RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims description 4
MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 claims description 4
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 4
TYCOFFBAZNSQOJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC(F)=C1 TYCOFFBAZNSQOJ-UHFFFAOYSA-N 0.000 claims description 4
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 4
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 4
QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 claims description 4
QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 4
UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 claims description 4
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 4
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 4
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 4
XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
108090000978 Interleukin-4 Proteins 0.000 claims description 4
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 4
MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 4
229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims description 4
CQSRTOJJBONKMC-VHEBQXMUSA-N OC(=O)CNC(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O Chemical compound OC(=O)CNC(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O CQSRTOJJBONKMC-VHEBQXMUSA-N 0.000 claims description 4
108091005804 Peptidases Proteins 0.000 claims description 4
239000004365 Protease Substances 0.000 claims description 4
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 4
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims description 4
HBAIZOJDXAXWHS-UHFFFAOYSA-M Sodium thiosalicylate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1S HBAIZOJDXAXWHS-UHFFFAOYSA-M 0.000 claims description 4
XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims description 4
208000036142 Viral infection Diseases 0.000 claims description 4
229960004748 abacavir Drugs 0.000 claims description 4
MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims description 4
229960001830 amprenavir Drugs 0.000 claims description 4
YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims description 4
229960004168 balsalazide Drugs 0.000 claims description 4
IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 claims description 4
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 4
229940092705 beclomethasone Drugs 0.000 claims description 4
229960002537 betamethasone Drugs 0.000 claims description 4
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 4
229960002716 bromfenac sodium Drugs 0.000 claims description 4
HZFGMQJYAFHESD-UHFFFAOYSA-M bromfenac sodium Chemical compound [Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 HZFGMQJYAFHESD-UHFFFAOYSA-M 0.000 claims description 4
229960004436 budesonide Drugs 0.000 claims description 4
229960002688 choline salicylate Drugs 0.000 claims description 4
229960004544 cortisone Drugs 0.000 claims description 4
239000000430 cytokine receptor antagonist Substances 0.000 claims description 4
229960005319 delavirdine Drugs 0.000 claims description 4
229960003957 dexamethasone Drugs 0.000 claims description 4
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
229960003804 efavirenz Drugs 0.000 claims description 4
XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims description 4
229960005293 etodolac Drugs 0.000 claims description 4
235000008524 evening primrose extract Nutrition 0.000 claims description 4
229940089020 evening primrose oil Drugs 0.000 claims description 4
239000010475 evening primrose oil Substances 0.000 claims description 4
229960001419 fenoprofen Drugs 0.000 claims description 4
229960000676 flunisolide Drugs 0.000 claims description 4
229950001284 fluprofen Drugs 0.000 claims description 4
229960002390 flurbiprofen Drugs 0.000 claims description 4
239000006260 foam Substances 0.000 claims description 4
239000000499 gel Substances 0.000 claims description 4
229960000890 hydrocortisone Drugs 0.000 claims description 4
229960001936 indinavir Drugs 0.000 claims description 4
229950008410 ipsalazide Drugs 0.000 claims description 4
229960000991 ketoprofen Drugs 0.000 claims description 4
229960004384 ketorolac tromethamine Drugs 0.000 claims description 4
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 claims description 4
229940072082 magnesium salicylate Drugs 0.000 claims description 4
229960003464 mefenamic acid Drugs 0.000 claims description 4
229960004584 methylprednisolone Drugs 0.000 claims description 4
229960000884 nelfinavir Drugs 0.000 claims description 4
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 4
229960000689 nevirapine Drugs 0.000 claims description 4
229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims description 4
239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims description 4
QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 claims description 4
229960004110 olsalazine Drugs 0.000 claims description 4
229960002739 oxaprozin Drugs 0.000 claims description 4
OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 claims description 4
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 4
229960005205 prednisolone Drugs 0.000 claims description 4
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 4
230000000069 prophylactic effect Effects 0.000 claims description 4
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 4
229960000311 ritonavir Drugs 0.000 claims description 4
NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 4
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 4
229960000371 rofecoxib Drugs 0.000 claims description 4
229960004889 salicylic acid Drugs 0.000 claims description 4
229940058287 salicylic acid derivative anticestodals Drugs 0.000 claims description 4
150000003872 salicylic acid derivatives Chemical class 0.000 claims description 4
229960001852 saquinavir Drugs 0.000 claims description 4
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical group C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 4
229960004025 sodium salicylate Drugs 0.000 claims description 4
229960003703 sodium thiosalicylate Drugs 0.000 claims description 4
229960001940 sulfasalazine Drugs 0.000 claims description 4
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 4
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 4
229960004492 suprofen Drugs 0.000 claims description 4
229960001017 tolmetin Drugs 0.000 claims description 4
FQCQGOZEWWPOKI-UHFFFAOYSA-K trisalicylate-choline Chemical compound [Mg+2].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O FQCQGOZEWWPOKI-UHFFFAOYSA-K 0.000 claims description 4
229960000523 zalcitabine Drugs 0.000 claims description 4
239000006071 cream Substances 0.000 claims description 3
239000003862 glucocorticoid Substances 0.000 claims description 3
210000003750 lower gastrointestinal tract Anatomy 0.000 claims description 3
238000011321 prophylaxis Methods 0.000 claims description 3
239000006213 vaginal ring Substances 0.000 claims description 3
229940044953 vaginal ring Drugs 0.000 claims description 3
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 9
102100034343 Integrase Human genes 0.000 claims 7
239000002777 nucleoside Substances 0.000 claims 6
150000003833 nucleoside derivatives Chemical class 0.000 claims 6
VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 3
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 3
108070000030 Viral receptors Proteins 0.000 claims 3
229960001259 diclofenac Drugs 0.000 claims 3
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 3
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims 3
239000012634 fragment Substances 0.000 claims 3
CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims 3
229940083542 sodium Drugs 0.000 claims 3
102100022339 Integrin alpha-L Human genes 0.000 claims 2
108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 2
210000004962 mammalian cell Anatomy 0.000 claims 2
210000005260 human cell Anatomy 0.000 claims 1
238000007910 systemic administration Methods 0.000 claims 1
230000009885 systemic effect Effects 0.000 claims 1
101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 121
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 121
230000014509 gene expression Effects 0.000 description 62
210000004698 lymphocyte Anatomy 0.000 description 60
210000004369 blood Anatomy 0.000 description 47
239000008280 blood Substances 0.000 description 47
210000001744 T-lymphocyte Anatomy 0.000 description 44
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 44
238000001574 biopsy Methods 0.000 description 43
210000004877 mucosa Anatomy 0.000 description 42
230000001965 increasing effect Effects 0.000 description 41
206010061218 Inflammation Diseases 0.000 description 39
230000004054 inflammatory process Effects 0.000 description 39
210000001035 gastrointestinal tract Anatomy 0.000 description 31
230000000694 effects Effects 0.000 description 28
238000002560 therapeutic procedure Methods 0.000 description 27
230000001413 cellular effect Effects 0.000 description 26
239000002245 particle Substances 0.000 description 25
102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 24
101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 24
101710147327 Calcineurin B homologous protein 1 Proteins 0.000 description 23
101710205625 Capsid protein p24 Proteins 0.000 description 23
101710177166 Phosphoprotein Proteins 0.000 description 23
101710149279 Small delta antigen Proteins 0.000 description 23
102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 23
239000003814 drug Substances 0.000 description 23
238000011282 treatment Methods 0.000 description 23
230000005540 biological transmission Effects 0.000 description 22
210000005087 mononuclear cell Anatomy 0.000 description 21
241000713772 Human immunodeficiency virus 1 Species 0.000 description 20
108010002350 Interleukin-2 Proteins 0.000 description 17
102000000588 Interleukin-2 Human genes 0.000 description 17
238000002955 isolation Methods 0.000 description 14
210000001072 colon Anatomy 0.000 description 13
150000001875 compounds Chemical class 0.000 description 13
208000022559 Inflammatory bowel disease Diseases 0.000 description 12
201000010099 disease Diseases 0.000 description 12
229940079593 drug Drugs 0.000 description 12
238000000684 flow cytometry Methods 0.000 description 12
108090000623 proteins and genes Proteins 0.000 description 12
208000030507 AIDS Diseases 0.000 description 11
239000006228 supernatant Substances 0.000 description 11
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 10
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 10
102000001327 Chemokine CCL5 Human genes 0.000 description 10
108010055166 Chemokine CCL5 Proteins 0.000 description 10
238000001861 endoscopic biopsy Methods 0.000 description 10
239000000523 sample Substances 0.000 description 10
206010028116 Mucosal inflammation Diseases 0.000 description 9
230000029812 viral genome replication Effects 0.000 description 9
206010038997 Retroviral infections Diseases 0.000 description 8
229940072224 asacol Drugs 0.000 description 8
238000003556 assay Methods 0.000 description 8
230000028709 inflammatory response Effects 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
230000009467 reduction Effects 0.000 description 8
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 7
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 7
102100034349 Integrase Human genes 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 7
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 7
102100040247 Tumor necrosis factor Human genes 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
229940088598 enzyme Drugs 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
239000002609 medium Substances 0.000 description 7
244000052769 pathogen Species 0.000 description 7
230000004044 response Effects 0.000 description 7
206010009900 Colitis ulcerative Diseases 0.000 description 6
102000029816 Collagenase Human genes 0.000 description 6
108060005980 Collagenase Proteins 0.000 description 6
102000006354 HLA-DR Antigens Human genes 0.000 description 6
108010058597 HLA-DR Antigens Proteins 0.000 description 6
241000282412 Homo Species 0.000 description 6
201000006704 Ulcerative Colitis Diseases 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
229960002424 collagenase Drugs 0.000 description 6
108010007093 dispase Proteins 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
238000005259 measurement Methods 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
230000001717 pathogenic effect Effects 0.000 description 6
239000000047 product Substances 0.000 description 6
238000010186 staining Methods 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
230000002103 transcriptional effect Effects 0.000 description 6
206010001513 AIDS related complex Diseases 0.000 description 5
101150013553 CD40 gene Proteins 0.000 description 5
102100032937 CD40 ligand Human genes 0.000 description 5
238000002965 ELISA Methods 0.000 description 5
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 5
108060001084 Luciferase Proteins 0.000 description 5
239000005089 Luciferase Substances 0.000 description 5
241000282553 Macaca Species 0.000 description 5
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 5
108010067390 Viral Proteins Proteins 0.000 description 5
239000000427 antigen Substances 0.000 description 5
108091007433 antigens Proteins 0.000 description 5
102000036639 antigens Human genes 0.000 description 5
210000003719 b-lymphocyte Anatomy 0.000 description 5
210000004970 cd4 cell Anatomy 0.000 description 5
230000034303 cell budding Effects 0.000 description 5
230000030833 cell death Effects 0.000 description 5
210000000170 cell membrane Anatomy 0.000 description 5
230000008859 change Effects 0.000 description 5
206010009887 colitis Diseases 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
230000006870 function Effects 0.000 description 5
210000005205 gut mucosa Anatomy 0.000 description 5
210000003563 lymphoid tissue Anatomy 0.000 description 5
230000036210 malignancy Effects 0.000 description 5
230000001566 pro-viral effect Effects 0.000 description 5
230000008569 process Effects 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
238000011084 recovery Methods 0.000 description 5
241000894007 species Species 0.000 description 5
210000002845 virion Anatomy 0.000 description 5
108010029697 CD40 Ligand Proteins 0.000 description 4
206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 4
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 4
206010049025 Persistent generalised lymphadenopathy Diseases 0.000 description 4
239000004698 Polyethylene Substances 0.000 description 4
102000052575 Proto-Oncogene Human genes 0.000 description 4
108700020978 Proto-Oncogene Proteins 0.000 description 4
108020000999 Viral RNA Proteins 0.000 description 4
239000002253 acid Substances 0.000 description 4
230000000840 anti-viral effect Effects 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
238000000605 extraction Methods 0.000 description 4
230000002519 immonomodulatory effect Effects 0.000 description 4
230000008629 immune suppression Effects 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
230000003960 inflammatory cascade Effects 0.000 description 4
210000000265 leukocyte Anatomy 0.000 description 4
210000000207 lymphocyte subset Anatomy 0.000 description 4
210000005210 lymphoid organ Anatomy 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
229940094443 oxytocics prostaglandins Drugs 0.000 description 4
201000003450 persistent generalized lymphadenopathy Diseases 0.000 description 4
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 4
150000003180 prostaglandins Chemical class 0.000 description 4
230000028327 secretion Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
230000009466 transformation Effects 0.000 description 4
230000001131 transforming effect Effects 0.000 description 4
102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
241000714165 Feline leukemia virus Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 3
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 3
241000713821 Mason-Pfizer monkey virus Species 0.000 description 3
SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 3
241000714177 Murine leukemia virus Species 0.000 description 3
108700020796 Oncogene Proteins 0.000 description 3
241001494479 Pecora Species 0.000 description 3
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
210000000601 blood cell Anatomy 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
241001493065 dsRNA viruses Species 0.000 description 3
230000012953 feeding on blood of other organism Effects 0.000 description 3
210000002865 immune cell Anatomy 0.000 description 3
238000011532 immunohistochemical staining Methods 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
238000002483 medication Methods 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
230000035772 mutation Effects 0.000 description 3
231100000590 oncogenic Toxicity 0.000 description 3
230000002246 oncogenic effect Effects 0.000 description 3
229960005489 paracetamol Drugs 0.000 description 3
230000008506 pathogenesis Effects 0.000 description 3
230000037361 pathway Effects 0.000 description 3
239000000816 peptidomimetic Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000001177 retroviral effect Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
229960001860 salicylate Drugs 0.000 description 3
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
230000001629 suppression Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
239000003826 tablet Substances 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
230000029302 virus maturation Effects 0.000 description 3
208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 2
208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
208000034048 Asymptomatic disease Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000714266 Bovine leukemia virus Species 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
206010061818 Disease progression Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
101710121417 Envelope glycoprotein Proteins 0.000 description 2
108700039887 Essential Genes Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
101710177291 Gag polyprotein Proteins 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
241000714259 Human T-lymphotropic virus 2 Species 0.000 description 2
241000713673 Human foamy virus Species 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
206010025327 Lymphopenia Diseases 0.000 description 2
ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
208000025966 Neurological disease Diseases 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
208000001388 Opportunistic Infections Diseases 0.000 description 2
108010004729 Phycoerythrin Proteins 0.000 description 2
241000712907 Retroviridae Species 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
108700012920 TNF Proteins 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
108010003533 Viral Envelope Proteins Proteins 0.000 description 2
241000713325 Visna/maedi virus Species 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
238000007792 addition Methods 0.000 description 2
239000000654 additive Substances 0.000 description 2
201000006966 adult T-cell leukemia Diseases 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000036436 anti-hiv Effects 0.000 description 2
229940124599 anti-inflammatory drug Drugs 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
229940124977 antiviral medication Drugs 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000003305 autocrine Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
239000010836 blood and blood product Substances 0.000 description 2
229940125691 blood product Drugs 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
108091092328 cellular RNA Proteins 0.000 description 2
230000007541 cellular toxicity Effects 0.000 description 2
230000014564 chemokine production Effects 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
230000034994 death Effects 0.000 description 2
210000004443 dendritic cell Anatomy 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
230000006866 deterioration Effects 0.000 description 2
KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 2
230000029087 digestion Effects 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
230000005750 disease progression Effects 0.000 description 2
238000009826 distribution Methods 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
238000001839 endoscopy Methods 0.000 description 2
NNYBQONXHNTVIJ-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-UHFFFAOYSA-N 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
238000010191 image analysis Methods 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
150000002617 leukotrienes Chemical class 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
231100001023 lymphopenia Toxicity 0.000 description 2
239000000463 material Substances 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
229960001929 meloxicam Drugs 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
238000007427 paired t-test Methods 0.000 description 2
230000003076 paracrine Effects 0.000 description 2
210000004976 peripheral blood cell Anatomy 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229960002895 phenylbutazone Drugs 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
238000009258 post-therapy Methods 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
238000011002 quantification Methods 0.000 description 2
238000003753 real-time PCR Methods 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000007480 spreading Effects 0.000 description 2
238000003892 spreading Methods 0.000 description 2
239000002294 steroidal antiinflammatory agent Substances 0.000 description 2
230000003637 steroidlike Effects 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
230000008685 targeting Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
238000013519 translation Methods 0.000 description 2
230000035899 viability Effects 0.000 description 2
230000017613 viral reproduction Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
XTYSXGHMTNTKFH-BDEHJDMKSA-N (2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;hydrate Chemical compound O.C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 XTYSXGHMTNTKFH-BDEHJDMKSA-N 0.000 description 1
LJQDDVJEZIEHNY-YIMUCPRWSA-N (4r)-4-[(5r,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-n,n-dimethylpentan-1-amine Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCCN(C)C)C)[C@@]2(C)CC1 LJQDDVJEZIEHNY-YIMUCPRWSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
QBWLKDFBINPHFT-UHFFFAOYSA-L 1,3,2$l^{2}-benzodioxabismin-4-one;hydrate Chemical compound O.C1=CC=C2C(=O)O[Bi]OC2=C1 QBWLKDFBINPHFT-UHFFFAOYSA-L 0.000 description 1
XOZLRRYPUKAKMU-UHFFFAOYSA-N 1,5-dimethyl-2-phenyl-4-(propan-2-ylamino)-3-pyrazolone Chemical compound O=C1C(NC(C)C)=C(C)N(C)N1C1=CC=CC=C1 XOZLRRYPUKAKMU-UHFFFAOYSA-N 0.000 description 1
MLKXDPUZXIRXEP-UHFFFAOYSA-N 2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]-1-indenyl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2C1=CC1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-UHFFFAOYSA-N 0.000 description 1
KPIVDNYJNOPGBE-UHFFFAOYSA-N 2-aminonicotinic acid Chemical class NC1=NC=CC=C1C(O)=O KPIVDNYJNOPGBE-UHFFFAOYSA-N 0.000 description 1
PYSICVOJSJMFKP-UHFFFAOYSA-N 3,5-dibromo-2-chloropyridine Chemical compound ClC1=NC=C(Br)C=C1Br PYSICVOJSJMFKP-UHFFFAOYSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
108700012813 7-aminoactinomycin D Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
108010041397 CD4 Antigens Proteins 0.000 description 1
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
108010061299 CXCR4 Receptors Proteins 0.000 description 1
102000012000 CXCR4 Receptors Human genes 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
101150015280 Cel gene Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
102000018704 Chitinase-3-Like Protein 1 Human genes 0.000 description 1
108010066813 Chitinase-3-Like Protein 1 Proteins 0.000 description 1
101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
206010011968 Decreased immune responsiveness Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
206010018746 Growth accelerated Diseases 0.000 description 1
108010027044 HIV Core Protein p24 Proteins 0.000 description 1
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 1
101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
208000033089 Human immunodeficiency virus transmission Diseases 0.000 description 1
241000714192 Human spumaretrovirus Species 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
208000036747 Infectious transmissions Diseases 0.000 description 1
102100034353 Integrase Human genes 0.000 description 1
102100025390 Integrin beta-2 Human genes 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000019223 Interleukin-1 receptor Human genes 0.000 description 1
108050006617 Interleukin-1 receptor Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000032420 Latent Infection Diseases 0.000 description 1
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
239000000232 Lipid Bilayer Substances 0.000 description 1
102000003820 Lipoxygenases Human genes 0.000 description 1
108090000128 Lipoxygenases Proteins 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
102000043131 MHC class II family Human genes 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
206010064912 Malignant transformation Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
102000014171 Milk Proteins Human genes 0.000 description 1
108010011756 Milk Proteins Proteins 0.000 description 1
101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241000186359 Mycobacterium Species 0.000 description 1
108010057466 NF-kappa B Proteins 0.000 description 1
102000003945 NF-kappa B Human genes 0.000 description 1
BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
238000009004 PCR Kit Methods 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
238000010222 PCR analysis Methods 0.000 description 1
238000002944 PCR assay Methods 0.000 description 1
SGUKUZOVHSFKPH-UHFFFAOYSA-N PGG2 Natural products C1C2OOC1C(C=CC(OO)CCCCC)C2CC=CCCCC(O)=O SGUKUZOVHSFKPH-UHFFFAOYSA-N 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
208000016012 Phenotypic abnormality Diseases 0.000 description 1
102100026918 Phospholipase A2 Human genes 0.000 description 1
108010058864 Phospholipases A2 Proteins 0.000 description 1
102000004211 Platelet factor 4 Human genes 0.000 description 1
108090000778 Platelet factor 4 Proteins 0.000 description 1
208000037062 Polyps Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
206010036774 Proctitis Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
238000011529 RT qPCR Methods 0.000 description 1
208000005074 Retroviridae Infections Diseases 0.000 description 1
241000713675 Spumavirus Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
UNZIDPIPYUMVPA-UHFFFAOYSA-M Sulpyrine Chemical compound O.[Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 UNZIDPIPYUMVPA-UHFFFAOYSA-M 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
230000006043 T cell recruitment Effects 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
210000000662 T-lymphocyte subset Anatomy 0.000 description 1
208000026062 Tissue disease Diseases 0.000 description 1
102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
206010044696 Tropical spastic paresis Diseases 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
206010058874 Viraemia Diseases 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
229940068372 acetyl salicylate Drugs 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
108010013985 adhesion receptor Proteins 0.000 description 1
102000019997 adhesion receptor Human genes 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229940013181 advil Drugs 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229940060515 aleve Drugs 0.000 description 1
239000003708 ampul Substances 0.000 description 1
229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
229940089918 ansaid Drugs 0.000 description 1
RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000011225 antiretroviral therapy Methods 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
210000001099 axilla Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
229960000782 bismuth subsalicylate Drugs 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
229960000590 celecoxib Drugs 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
230000006041 cell recruitment Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
235000019804 chlorophyll Nutrition 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
230000003475 colitic effect Effects 0.000 description 1
210000004953 colonic tissue Anatomy 0.000 description 1
238000005094 computer simulation Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
108091008034 costimulatory receptors Proteins 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
229960001193 diclofenac sodium Drugs 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
229960002986 dinoprostone Drugs 0.000 description 1
229940120889 dipyrone Drugs 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
150000002066 eicosanoids Chemical class 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
108010078428 env Gene Products Proteins 0.000 description 1
230000009483 enzymatic pathway Effects 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
230000008995 epigenetic change Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000003386 epithelial cell of thymus gland Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
108010052621 fas Receptor Proteins 0.000 description 1
102000018823 fas Receptor Human genes 0.000 description 1
229940065410 feldene Drugs 0.000 description 1
RDJGLLICXDHJDY-UHFFFAOYSA-N fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
229960005341 fenoprofen calcium Drugs 0.000 description 1
VHUXSAWXWSTUOD-UHFFFAOYSA-L fenoprofen calcium (anhydrous) Chemical compound [Ca+2].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1.[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 VHUXSAWXWSTUOD-UHFFFAOYSA-L 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 description 1
229960000588 flunixin Drugs 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
235000020664 gamma-linolenic acid Nutrition 0.000 description 1
229960002733 gamolenic acid Drugs 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229960002743 glutamine Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000005090 green fluorescent protein Substances 0.000 description 1
210000004013 groin Anatomy 0.000 description 1
230000035876 healing Effects 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
208000035861 hematochezia Diseases 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
230000000423 heterosexual effect Effects 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
210000003297 immature b lymphocyte Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000007233 immunological mechanism Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000002584 immunomodulator Effects 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000010249 in-situ analysis Methods 0.000 description 1
229940089536 indocin Drugs 0.000 description 1
150000002476 indolines Chemical class 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000037456 inflammatory mechanism Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000002743 insertional mutagenesis Methods 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
210000000867 larynx Anatomy 0.000 description 1
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
235000020778 linoleic acid Nutrition 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000022288 lymphocyte chemotaxis Effects 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000036212 malign transformation Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000035800 maturation Effects 0.000 description 1
210000003519 mature b lymphocyte Anatomy 0.000 description 1
229960003803 meclofenamic acid Drugs 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000034217 membrane fusion Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
235000021239 milk protein Nutrition 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
229940072709 motrin Drugs 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
229960004270 nabumetone Drugs 0.000 description 1
229940089466 nalfon Drugs 0.000 description 1
229940090008 naprosyn Drugs 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
229960000965 nimesulide Drugs 0.000 description 1
HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
229960000649 oxyphenbutazone Drugs 0.000 description 1
CNDQSXOVEQXJOE-UHFFFAOYSA-N oxyphenbutazone hydrate Chemical compound O.O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 CNDQSXOVEQXJOE-UHFFFAOYSA-N 0.000 description 1
231100000255 pathogenic effect Toxicity 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229940072223 pentasa Drugs 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
230000002688 persistence Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
238000007747 plating Methods 0.000 description 1
108010089520 pol Gene Products Proteins 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000030786 positive chemotaxis Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
150000004672 propanoic acids Chemical class 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
SGUKUZOVHSFKPH-YNNPMVKQSA-N prostaglandin G2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](OO)CCCCC)[C@H]2C\C=C/CCCC(O)=O SGUKUZOVHSFKPH-YNNPMVKQSA-N 0.000 description 1
YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 1
KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000012268 protein inhibitor Substances 0.000 description 1
230000005892 protein maturation Effects 0.000 description 1
JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
229950000385 ramifenazone Drugs 0.000 description 1
206010037844 rash Diseases 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
230000010837 receptor-mediated endocytosis Effects 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
229940116176 remicade Drugs 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000002579 sigmoidoscopy Methods 0.000 description 1
230000011664 signaling Effects 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
230000001150 spermicidal effect Effects 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000007447 staining method Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000003068 static effect Effects 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
108091007466 transmembrane glycoproteins Proteins 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
208000006961 tropical spastic paraparesis Diseases 0.000 description 1
102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
229940072651 tylenol Drugs 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
210000003934 vacuole Anatomy 0.000 description 1
229940120293 vaginal suppository Drugs 0.000 description 1
239000006216 vaginal suppository Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000005570 vertical transmission Effects 0.000 description 1
230000007502 viral entry Effects 0.000 description 1
230000007733 viral latency Effects 0.000 description 1
230000007482 viral spreading Effects 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
AIDS & HIV (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Reproductive Health (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Plant Substances (AREA)
Orthopedics, Nursing, And Contraception (AREA)
Medicinal Preparation (AREA)

CA002368593A 1999-05-14 2000-05-12 Anti-inflammatory therapy for inflammatory mediated infection Abandoned CA2368593A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US13409199P	1999-05-14	1999-05-14
US60/134,091		1999-05-14
PCT/US2000/013142 WO2000069255A1 (en)	1999-05-14	2000-05-12	Anti-inflammatory therapy for inflammatory mediated infection

Publications (1)

Publication Number	Publication Date
CA2368593A1 true CA2368593A1 (en)	2000-11-23

Family

ID=22461735

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002368593A Abandoned CA2368593A1 (en)	1999-05-14	2000-05-12	Anti-inflammatory therapy for inflammatory mediated infection

Country Status (13)

Country	Link
EP (1)	EP1202620A1 (tr)
JP (1)	JP2002544210A (tr)
KR (1)	KR20020024587A (tr)
CN (1)	CN1353573A (tr)
AU (1)	AU5010800A (tr)
BR (1)	BR0010546A (tr)
CA (1)	CA2368593A1 (tr)
HK (1)	HK1047216A1 (tr)
IL (1)	IL146130A0 (tr)
MX (1)	MXPA01011606A (tr)
PL (1)	PL351710A1 (tr)
TR (1)	TR200103271T2 (tr)
WO (1)	WO2000069255A1 (tr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ524252A (en)	2000-07-20	2004-03-26	Lauras As	Cox-2 inhibitors for treating HIV and AIDS
MXPA04006572A (es) *	2002-01-10	2005-11-04	Upjohn Co	Terapia de combinacion antivirica.
AR039540A1 (es) *	2002-05-13	2005-02-23	Tibotec Pharm Ltd	Compuestos microbicidas con contenido de pirimidina o triazina
US6790867B2 (en) *	2002-05-20	2004-09-14	Schering-Plough Animal Health Corporation	Compositions and method for treating infection in cattle and swine
CN103143022A (zh)	2002-07-30	2013-06-12	奥默罗斯公司	眼科冲洗液及方法
ITMI20031311A1 (it) *	2003-06-27	2004-12-28	Indena Spa	Formulazioni per il trattamento di disturbi artrosici.
DE602004031356D1 (de) *	2003-11-21	2011-03-24	Zalicus Inc	Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
CN102002476B (zh) *	2010-08-20	2013-05-08	上海市公共卫生临床中心	一种体外培养人体黏膜活组织模型及其建立方法和应用
CN102557976B (zh) *	2010-12-15	2015-06-10	辽宁盛京制药有限公司	溴芬酸有机盐及其制备方法、其组合物及用途
EP2481751A1 (en) *	2011-01-26	2012-08-01	PharmaSurgics in Sweden AB	Human lactoferrin derived peptides
AU2013201465B2 (en)	2012-10-24	2016-03-03	Rayner Intraocular Lenses Limited	Stable preservative-free mydriatic and anti-inflammatory solutions for injection
CN104013959A (zh) *	2014-05-21	2014-09-03	郭和友	逆转录抑制剂和免疫抗体细胞三联合疗法
CN105456273A (zh) *	2014-09-02	2016-04-06	杭州雷索药业有限公司	奈韦拉平在制备抗炎药物中的应用
TWI705812B (zh)	2014-12-01	2020-10-01	奥默羅斯公司	用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
CN106176751A (zh) *	2016-08-18	2016-12-07	滨州医学院	茚地那韦增强糖皮质激素抗炎作用的医药新用途
CN106176739A (zh) *	2016-08-18	2016-12-07	滨州医学院	利托那韦增强糖皮质激素抗炎作用的医药新用途
CN106309445A (zh) *	2016-08-18	2017-01-11	滨州医学院	奈非那韦增强糖皮质激素抗炎作用的医药新用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5605885A (en) *	1988-05-05	1997-02-25	Entremed, Inc.	Method for stimulating the immune system
EP0407701A3 (en) *	1989-05-15	1992-04-22	Fujisawa Pharmaceutical Co., Ltd.	Antiretroviral pyrroline and pyrrolidine sulfonic acid derivatives
US5891924A (en) *	1996-09-26	1999-04-06	Research Development Foundation	Curcumin (diferuloylmethane) inhibition of NFκB activation

2000
- 2000-05-12 KR KR1020017014522A patent/KR20020024587A/ko not_active Ceased
- 2000-05-12 TR TR2001/03271T patent/TR200103271T2/tr unknown
- 2000-05-12 IL IL14613000A patent/IL146130A0/xx unknown
- 2000-05-12 HK HK02109002.5A patent/HK1047216A1/zh unknown
- 2000-05-12 EP EP00932379A patent/EP1202620A1/en not_active Withdrawn
- 2000-05-12 BR BR0010546-5A patent/BR0010546A/pt not_active Application Discontinuation
- 2000-05-12 PL PL00351710A patent/PL351710A1/xx not_active Application Discontinuation
- 2000-05-12 AU AU50108/00A patent/AU5010800A/en not_active Abandoned
- 2000-05-12 WO PCT/US2000/013142 patent/WO2000069255A1/en not_active Ceased
- 2000-05-12 MX MXPA01011606A patent/MXPA01011606A/es not_active Application Discontinuation
- 2000-05-12 JP JP2000617724A patent/JP2002544210A/ja active Pending
- 2000-05-12 CN CN00807547A patent/CN1353573A/zh active Pending
- 2000-05-12 CA CA002368593A patent/CA2368593A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2000069255A8 (en)	2001-03-22
EP1202620A1 (en)	2002-05-08
CN1353573A (zh)	2002-06-12
TR200103271T2 (tr)	2002-06-21
KR20020024587A (ko)	2002-03-30
BR0010546A (pt)	2002-03-05
PL351710A1 (en)	2003-06-02
MXPA01011606A (es)	2003-09-10
WO2000069255A1 (en)	2000-11-23
AU5010800A (en)	2000-12-05
JP2002544210A (ja)	2002-12-24
HK1047216A1 (zh)	2003-02-14
IL146130A0 (en)	2002-07-25

Legal Events

Date	Code	Title	Description
2001-10-31	EEER	Examination request
2007-02-28	FZDE	Discontinued

Publication	Publication Date	Title
De Luca et al.	2023	Lichen sclerosus: the 2023 update
EP1202620A1 (en)	2002-05-08	Anti-inflammatory therapy for inflammatory mediated infection
Patterson et al.	1998	Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission
Wei et al.	2003	Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition
Klatt	2015	Pathology of AIDS
Corbeau et al.	2011	Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection
Utay et al.	2016	Role of immune activation in progression to AIDS
Nilsson et al.	2007	Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection
Kotler et al.	1998	Effect of combination antiretroviral therapy upon rectal mucosal HIV RNA burden and mononuclear cell apoptosis
US20030138399A1 (en)	2003-07-24	Anti-inflammatory therapy for inflammatory mediated infection
Shacklett et al.	2004	Abundant expression of granzyme A, but not perforin, in granules of CD8+ T cells in GALT: implications for immune control of HIV-1 infection
Mehraj et al.	2014	Immune suppression by myeloid cells in HIV infection: new targets for immunotherapy
Behbahani et al.	2007	Proinflammatory and type 1 cytokine expression in cervical mucosa during HIV-1 and human papillomavirus infection
Niu et al.	1993	Summary of the National Institutes of Health Workshop on Primary Human Immunodeficiency Virus Type 1 Infection1, 2
Wu et al.	2025	Targeting IRE1α improves insulin sensitivity and thermogenesis and suppresses metabolically active adipose tissue macrophages in male obese mice
Van Deventer	1999	Anti-TNF antibody treatment of Crohn's disease
Pan et al.	1998	Calmodulin antagonists inhibit apoptosis of CD4+ T-cells from patients with AIDS
Xu et al.	2018	Inflammation and outer blood-retina barrier (BRB) compromise following choroidal murine cytomegalovirus (MCMV) infections
Santucci et al.	2005	Different Sensitivity of Lamina Propria T-Cell Subsets to Nitric Oxide-Induced Apoptosis Explains Immunomodulatory Activity of a Nitric Oxide--Releasing Derivative of Mesalamine in Rodent Colitis
Kleinman et al.	2020	Pharmacokinetics and immunological effects of romidepsin in rhesus macaques
De Biasi et al.	2011	HIV-1 infection and the aging of the immune system: facts, similarities and perspectives
Nair et al.	2004	Association of drug abuse with inhibition of HIV-1 immune responses: studies with long-term of HIV-1 non-progressors
Howard et al.	2007	Mucosal challenge with cell‐associated or cell‐free feline immunodeficiency virus induces rapid and distinctly different patterns of phenotypic change in the mucosal and systemic immune systems
Wilkinson et al.	2001	Immune interventions: The changing face of HIV and AIDS
Edzeamey et al.	2018	HIV Infection and Therapeutic Interventions: Review on HIV Infection Biology, Highly Active Antiretroviral Therapy (HAARTs), Hepatotoxicity, Nephrotoxicity and Dyslipidemia